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ABSTRACT
The two paralogous zinc finger factors CTCF and
CTCFL differ in expression such that CTCF is ubiq-
uitously expressed, whereas CTCFL is found during
spermatogenesis and in some cancer types in addi-
tion to other cell types. Both factors share the highly
conserved DNA binding domain and are bound to
DNA sequences with an identical consensus. In con-
trast, both factors differ substantially in the number
of bound sites in the genome. Here, we addressed
the molecular features for this binding specificity.
In contrast to CTCF we found CTCFL highly en-
riched at ‘open’ chromatin marked by H3K27 acety-
lation, H3K4 di- and trimethylation, H3K79 dimethy-
lation and H3K9 acetylation plus the histone vari-
ant H2A.Z. CTCFL is enriched at transcriptional
start sites and regions bound by transcription fac-
tors. Consequently, genes deregulated by CTCFL are
highly cell specific. In addition to a chromatin-driven
choice of binding sites, we determined nucleotide
positions critical for DNA binding by CTCFL, but not
by CTCF.
INTRODUCTION
In recent years the multifunctional and highly conserved
factor CTCF (CCCTC-binding factor) has been identified
as a key player in 3D chromatin architecture and gene reg-
ulation (1–3). CTCF binds DNA through a combination of
11 zinc-fingers from its centralDNAbinding domain (4). At
its binding sites it can interact with a variety of co-factors,
most importantly the cohesin complex to mediate the for-
mation of long-distance DNA interaction and DNA loops
(5). Such looping events can then link three-dimensional ge-
nomic architecture to a functional output such as the reg-
ulation of genes through an enhancer or insulator (6). Uti-
lizing techniques like 3C (chromatin conformation capture)
and its genome-wide derivatives such as Hi-C, topologically
associated domains (TADs) could be identified and CTCF
was found to be enriched in the border areas of such do-
mains (7). Disruption of CTCF binding and binding sites
leads to changes in TAD patterns and has effects on proper
gene expression programs (8). Taken together, CTCF is one
of the central factors in bridging genome architecture to
function.
In contrast to the established role of CTCF, the cellular
role of the only known CTCF-paralogue, CTCFL, remains
to be solved. CTCFL was identified in 2002 (9) and is be-
lieved to result from a gene duplication event in the early
amniotic evolution (10), with CTCF and CTCFL sharing a
highly conserved 11 zinc finger (ZF) DNA binding domain.
The N- and C-termini of the two proteins are different, with
an amino acid similarity of<20% between mammalian ver-
sions (11). First reports described CTCFL expression to be
testis specific and mutually exclusive to CTCF. Later, more
detailed analysis could show CTCFL to be transiently ex-
pressed during spermatogenesis, prior to the onset of meio-
sis, overlapping with CTCF expression (12). Some func-
tional differences regarding the two proteins have been iden-
tified, for instance it seems that only CTCF binds compo-
nents of the Cohesin complex like Smc1 in mouse (12) or
RAD21 in human (13). CTCFL also failed to substitute
for a loss of CTCF in CTCF KO experiments (12). Further
Knockout experiments of CTCFL showed it to be impor-
tant in proper testicular development. This is exemplified by
the deregulation of important testis-specific genes, such as
Gal3st1 and Prss50 (12,14,15). Tissue specificity of CTCFL
expression has been questioned (16) by showing a more
widespread expression in normal and in cancer cells. Aber-
rant expression of CTCFL was identified in some cancers
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(17–19). Research to identify CTCFL as a biomarker for
specific cancer types (20) and for therapeutical approaches
has been followed up (21).
With the advent of next-generation-sequencing many ad-
vances in the field of DNA binding factors have been made.
Also for CTCFL, the genome-wide binding patterns have
been started to be explored (12,13). Sites of CTCFLbinding
strongly overlap with CTCF sites and the identified DNA
binding motifs of the two proteins are virtually identical
(12,13,22). CTCFL seems to preferentially bind to genomic
regions of active and open chromatin showing for exam-
ple an enrichment at transcriptional start sites compared
to CTCF (12). CTCFL binding is strongly associated with
the presence of active histone modifications like H3K4me3
or H3K27ac (12,13). Most recently, it could be shown that
CTCFL binds genomic sites characterized by the presence
of two CTCF-motifs in close proximity allowing for simul-
taneous binding of CTCF and CTCFL (13). In mouse and
human, the similarity between the ZF DNA binding do-
mains of the two proteins is ∼70%, on the amino acid level
(11), which also might explain some degree of differential
binding.
Thus, epigenetic marks and dual binding motifs con-
tribute to binding specificity. However, it has not been anal-
ysed, whether epigeneticmarks are solely responsible for the
binding specificity such that a closed site in a particular tis-
sue is not bound by CTCFL, but will be bound in another
tissue with an open chromatin conformation. Here, we find
that this is exactly the case. CTCF is binding irrespective
of chromatin ‘openness’, whereas CTCFL binding is regu-
lated by epigeneticmarks characteristic for open chromatin.
In addition, we find that not all CTCF sites can potentially
be bound by CTCFL; rather, DNA-sequence specificity re-
stricts CTCFL binding to a sub-set of CTCF sites.
MATERIALS AND METHODS
Cell culture and transfection
Murine NIH3T3 and P19 cells as well as human K562
cells were grown at 37◦C with 5% CO2 in Dulbecco’s mod-
ified Eagle’s medium supplemented with 10% (v/v) serum
and 1% PenStrep. Differentiation of P19 cells was achieved
by supplementing cells grown on adherent dishes with 10
M retinoic acid. Transfections were performed on ad-
herent cells using jetPEI reagent (Polyplus transfection),
which was used in accordance to the manufacturer’s in-
structions. To generate stable clones, cells were transfected
with pBI-EGFP-FLAG-mCtcfl and pTA-N, a Tet-off sys-
tem (Clonetech) turning off the expression of CTCFL in
the presence ofDoxycycline (2g/ml). The transfected cells
were selected for puromycin resistance starting 24 h after
transfection. The clones were selected in 96-well plates, ex-
panded and characterized by immunoblotting, RT-qPCR
and immunofluorescence. CTCFL expression was achieved
by growing the cells in medium lacking Doxycycline for 48
h.
ChIP-seq data analysis of K562 ENCODE data
The K562 pre-aligned ChIP-seq data (hg19) were down-
loaded from ENCODE (23) via the UCSC genome browser
portal (Supplementary Table S1) (24). CTCF and CTCFL
peaks were called by MACS2 with standard settings (25).
Peaks overlapping the ENCODE blacklisted regions for the
hg19 regions were removed from the analysis. The set of
peaks overlapping between both replicates were used for
subsequent analyses. We defined five different categories:
all CTCF sites, all CTCFL sites, CTCF/CTCFL co-bound
sites as well as CTCF or CTCFL stand-alone sites, re-
spectively. We defined two sites being overlapping in case
a minimal overlap of 1 bp between the two peak inter-
vals was observed. All downstream analysis was done in
R/BioConductor (26).
TheGenomicRanges BioCOnductor function reducewas
used in order to merge CTCF and CTCFL peaks to a
common set (27). Reads from bam files were imported
through Rsamtools functions (Morgan, M., Page`s, H.,
Obenchain, V. and Hayden, N. (2016) Rsamtools: Binary
alignment (BAM), FASTA, variant call (BCF), and tabix
file import. R package version 1.24.0.; http://bioconductor.
org/packages/release/bioc/html/Rsamtools.html.). We con-
structed a count matrix containing information about the
number of reads per individual peak for all ChIP-seq data
sets mentioned above using the countOverlaps function of
the GenomicRanges BioC package. Read counts per peak
were normalized using the FPKM (fragments per kilobase
per million of sequenced reads) method normalizing for the
total number of sequencing reads as well as for the size of
the given peak interval. In order to control for potential bi-
ases introduced by the ChIP-seq technology we decided to
subtract the corresponding FPKM value of the input con-
trol, respectively. We calculated the normalized read counts
per peak N as
Ni,k =
(
# reads per peakk,i
total # of readsi
− # reads per peakk, input
total # of readsinput
)
× 10
6 × 103
width of peakk
with i being the i-th data set and k indicating the peak index
ranging from 1 to the total number of peaks under analysis
(38 365).
The resulting count matrix was used for generating box-
plots in Figure 1 and Supplementary Figure S1. Statistical
differences between individual binding categories (CTCFL,
CTCF/CTCFL co-bound and CTCF or CTCFL stand-
alone sites) and the average CTCF site as reference were
calculated by Wilcoxon signed rank test (two-sided alter-
native: ‘binding in analyzed category is greater than that of
CTCF binding’). The corresponding code is available upon
request.
Comparison to genomic annotations
RefSeq gene annotations for Homo sapiens were down-
loaded from UCSC homepage (version hg19). Next the
genome was partitioned into the following intervals: tran-
scriptional start site (TSS;±1 kb aroundRefSeq start sites),
TSS upstream (−10 kb to −1 kb), transcriptional end sites
(TES; ±1 kb around transcriptional end sites), exons, in-
trons and everything not covered by these classes as inter-
genic. CTCFandCTCFLpeak rangeswere intersectedwith
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these annotation intervals and the relative association was
calculated (as fraction of the complete genome) and com-
pared to the genomic background distribution.
Chromatin immunoprecipitation (ChIP)
ChIP was performed in a one-day protocol as described in
(28). Confluent cells growing in 15 cm dishes were fixed with
a final concentration of 1% formaldehyde (Calbiochem) for
10 min and quenched for 5 min using 1/7 volume of 1 M
Glycine. Cells were washed twice with cold PBS and har-
vested in 1 ml PBS (+ 1 mM PMSF). After pelleting, cells
were taken up in 1 ml IP buffer (150 mM NaCl, 50 mM
Tris–HCl (pH 7.5), 5 mM EDTA, NP-40 (0.5% vol/vol),
Triton X-100 (1.0% vol/vol)), supplemented with protease
inhibitors (Complete Mini, Roche) per 107 cells and incu-
bated for 10 min in ice. The cell solution was then sonified
using a Bioruptor (Diagenode) for 15 cycles (30 s ON/OFF)
followed by pelleting of cell debris (10 min at 14 000 rpm).
The chromatin containing supernatant was transferred to
new tubes and diluted 1:10 with IP buffer. 1 ml of this di-
lution was used in each precipitation. Ten percent were al-
ways used in parallel as an input sample. The solution was
pre-cleared for 2 h using 30 l Protein-A/G-Agarose beads
(Calbiochem) by rotating at 4◦C. After mild centrifugation
(5 min; 2000 rpm) the supernatant solution was transferred
to new tubes and corresponding antibodies (CTCF N2.2
(29); CTCFL S6 (12)) were added over night at 4◦C on a ro-
tating wheel. The antibody/protein/DNA complexes were
bound by addition of 30 l Protein-A/G-Agarose beads for
2 h rotating at 4◦C. The beads were then washed 5 times
for 5 min using 1 ml IP buffer each. 100 l 10% Chelex 100
resin (Bio-Rad)was added to the beads, briefly vortexed and
boiled for 10 min. An optional Proteinase K digestion was
performed. Chelex and beads were spun down and 80 l
supernatant were transferred to a new tube. Beads were re-
suspended in 120 l MilliQ H2O, spun down and the su-
pernatant was pooled with the previous supernatant. This
solution was then ready for qPCR and library preparation.
Deep sequencing of ChIP DNA and bioinformatics analysis
Samples were prepared as described for ChIP, but the elu-
tion step after DNA purification was performed with H2O
instead of elution buffer. If necessary, samples generated
with the same antibody were pooled and volume was re-
duced by evaporation to 30 l to obtain at least 10 ng of
total DNA. Sequencing libraries were prepared from 10 ng
of immunoprecipitated DNA with the NEBNext ChIP-Seq
Library Prep Reagent (New England Biolabs) according
to manufacturer’s instructions. Cluster generation was per-
formed using the cBot (Illumina Inc.). Sequencingwas done
on the HiSeq 2500 (Illumina Inc.) using TruSeq SBS Kit v3
– HS (Illumina) for 50 cycles. Image analysis and base call-
ing were performed using the Illumina pipeline v 1.8 (Illu-
mina Inc.). Raw and processed data have been deposited in
the NCBI gene expression omnibus (GEO) under accession
number GSE103199.
ChIP-Seq reads were converted to fastq format and
aligned to a precompiled hg19 reference index with
BOWTIEwith -k option set to 1 (30). Sequencing data were
controlled for general quality features using FastQC (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/). Un-
ambiguously mapped and unique reads were kept for sub-
sequent generation of binding profiles and calling of peaks
using MACS v1. (25) at default settings. In case of 3T3
cells uninduced clone 34 served as reference sample. In
case of p19 we used corresponding input samples. All
downstream analyses were done in R/BioConductor (http:
//www.bioconductor.org).
Peaks identified by MACS at a Poisson P value < 10−5
and an FDR <5% were used for intersection analysis to
determine the overlap in pairwise comparisons. Two peaks
were determined to be overlapping in case they had a mini-
mal overlapping interval of 1 bp.
Analysis of CTCF core sequence preferences
The chromosomal locations, hg18 coordinates and CTCF
sequences of all CTCF motifs of ranks 1 to 1000 were used
as identified (31). We used the liftOver utility of the UCSC
genome browser for converting CTCFL and CTCF peak
intervals from hg18 to hg19 coordinates (32). The overlap
of CTCF and CTCFL peaks with each genomic instance of
the top 100 sequences was than calculated and presented as
percentages.
Comparison between gene expression changes and CTCFL
binding
CTCF/ CTCFL peaks were called as described above.
Additional information about the chromatin state of
CTCF/CTCFL sites was derived from publicly avail-
able H3K27ac data, which is known to mark active cis-
regulatory chromatin segments (33):
H3K27ac in NIH3T3-L1 cells: GEO GSM535751 (34)
H3K27ac in p19 cells: GEO GSM821507
H3K27ac in RA-treated p19
cells:
GEO GSM821510 (35)
H3K27ac peaks were called with MACS v1. In order to
assign genes to peaks we followed the association rule 1
proposed by the Bejerano lab (36). In this basal plus ex-
tension rule we defined basal regulatory regions as the re-
gion from −5000 to + 1000 bp around the TSS. We ex-
tended this region to maximally 500 kb until it reaches the
next neighboring basal domain. Using this set of regions,
we assigned each peak to one or multiple genes. Gene ex-
pression changes were determined by Affymetrix Gene ar-
rays and corresponding log2-transformed gene expression
changes were compared between all genes, genes bound by
CTCFL or genes bound by H3K27ac-overlapping CTCFL
binding sites. Wilcoxon signed rank test were performed in
order to test for statistical differences between groups.
RNA analysis
For microarray analysis RNA was also isolated using
RNeasy Mini Kit and Microarrays were performed using
either Affymetrix Gene 1.0 ST Platform (NIH3T3 cells) or
Affymetrix Gene 2.0 ST platform (P19 cells). In case of p19
cells, raw data was analysed using Affymetrix own software
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suite (Expression console & Transcriptome analysis con-
sole). In case of NIH3T3 cells, CEL files were processed us-
ing the Aroma.Affymetrix package with RMA background
subtraction and quantile normalization. Deregulated genes
were also verified by qPCR.
Electrophoretic mobility shift analysis (EMSA)
Radiolabeled DNA probes were generated by phosphory-
lation with gamma 32P ATP and subsequently annealed.
100 fMol of probes were incubated with 5 l of in
vitro produced protein (Promega TnT T7 Quick Coupled
Transcription/Translation System) per shift. The binding
reaction was performed in PBS (pH 7.4, supplemented with
5 mM MgCl2, 1 mM ZnCl2, 1 mM DTT, 0.1% NP-40
and 10% glycerol) for 20 min at room temperature in the
presence of 200 ng/l pdIdC and 25–100 ng/l salmon
sperm DNA. Protein–DNA complexes were analyzed on
nondenaturing polyacrylamide gels (5% acrylamide (w/v))
in TAE-buffer. Electrophoresis was performed at 4◦C with
a field strength of 12 V/cm for 3–4 h.
Oligonucleotides
Sequences of the genomic regions used in the band shift ex-
periments are listed in Supplementary Table S2.
RESULTS
Active chromatin marks correlate with CTCFL binding
Previous publications have addressed the binding specificity
of CTCF and CTCFL in respect to clustering of binding
sites (13) and to active chromatin marks (12). Here, we
wanted to systematically address the binding determinants
of CTCF as compared to CTCFL. We utilized the exten-
sive ENCODE database available for K562 cells to iden-
tify possible chromatin marks or transcription factors en-
riched at CTCF or CTCFL binding sites. K562 cells are
positive for CTCF as well as for CTCFL. We first anal-
ysed the general overlap of binding sites between the two
proteins (Figure 1A). There are 38 365 CTCF binding sites
compared to only 13 292 for CTCFL with a shared frac-
tion of 9,397 sites. This means that 70% of CTCFL sites
are also occupied by CTCF in K562 cells. We then clas-
sified the binding sites for the two proteins in 5 different
groups: all CTCF sites (CTCF), all CTCFL sites (CTCFL),
shared sites (CTCF + CTCFL), only CTCF bound (CTCF
only) and only CTCFL bound sites (CTCFL only). To as-
sess the occupancy of histone marks and of DNA binding
factors over the selected subgroups of binding sites we re-
trieved the respective datasets from the ENCODE database
(Supplementary Table S1) and box plotted the log2 trans-
formed IP signal/Input for each factor over a 500 bp win-
dow around the identified binding sites. For the five histone
modificationsH3K27 acetylation,H3K4 dimethylation and
trimethylation, H3K79 dimethylation and H3K9 acetyla-
tion plus the histone variant H2A.Z, which are all associ-
ated with an active, open chromatin conformation, we see a
strong enrichment at sites with sole CTCFLbinding (Figure
1B, blue) and very weak levels at sole CTCF binding sites
(Figure 1B, green). Such a distinctive behaviour could not
be seen for histone marks not associated with active chro-
matin (Supplementary Figure S1). When analysing the oc-
cupancies of known transcription factors, the same correla-
tion with sole CTCFL binding sites can be seen. The identi-
fied factors are CREB1, ETS1, FOS, HDAC2, TAF7, YY1,
POL2 and ZBTB7, all of which show the highest levels of
binding in the CTCFL-only subgroup (Figure 1C, blue).
In order to challenge the correlation of CTCFL binding
sites with open chromatin we used ENCODE DNaseI data
in comparison to the five CTCF/CTCFL groups (Figure
1D).This again shows a significant correlation of CTCFL-
only sites with open chromatin (DNaseI sensitive). In con-
trast to the above transcription factors, both cohesin fac-
tors RAD21 and SMC3 are specifically depleted within the
CTCFL-only subgroup (Figure 1E, blue). For both cohesin
components an important co-association with CTCF has
been shown (5,6,37,38), mediating three-dimensional long-
range chromatin contacts. This finding supports previous
results showing that the cohesin complex can be specifically
recruited by CTCF, rather than by CTCFL (13). Recruit-
ment is mediated by binding of the cohesin component SA2
(39) to the C-terminal domain of CTCF, which differs from
the C-terminal domain of CTCFL.
Taken together, we identified a strong positive correlation
of active chromatin marks and transcription factors with
CTCFL, which is not seen for CTCF. In contrast, cohesin
complex components are enriched at CTCF-only sites and
depleted from CTCFL-only locations.
Cell-specific binding of CTCFL is driven by chromatin ‘open-
ness’
CTCFL expression is highly restricted to spermatogenesis
and to specific cancer types and cell lines (see K562 cells
above) and occurs in addition to the ubiquitous expression
of CTCF. In order to analyse the binding specificity of both
factors, wemimicked the in vivo situation by conditional ex-
pression of CTCFL in cell lines in addition to the endoge-
nous expression of CTCF. We generated CTCFL express-
ing mouse NIH3T3 and P19 cell clones. To investigate pos-
sible cell-type specific binding patterns for CTCFL due to
differential chromatin composition we generated genome-
wide bindingmaps in the inducibleNIH3T3 and P19 clones.
First, we confirmed the specificity of the antibodies used.
The CTCFL antibody (CTCFL S6 (12)) specifically recog-
nizes murine CTCFL and not human CTCFL (Supplemen-
tary Figure S2). In addition to western blots, the most strin-
gent tests for specificity are ChIP experiments. The CTCF
antibody shows ChIPseq signals at sites known to be bound
by CTCF (29). The CTCFL antibody is specific for CTCFL
as ChIPseq peaks are only detectable after CTCFL expres-
sion (Supplementary Figures S3 and S4) and a substantial
number of sites are specific for CTCFLand devoid of CTCF
(Supplementary Figure S4 and see below, Figure 2B). We
than studied the general distribution of the factors over ge-
nomic features in the two cell clones. We mapped the bind-
ing sites to the features and compared these fractions with
the genomic percentage of these features (Figure 2A). In the
cell clones we find the genomic associations to be fairly simi-
lar. CTCFL shows in both cell types a higher enrichment for
regions associated with open chromatin, like TSSs (40), as
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Figure 1. CTCFL binding events positively correlate with active histone modifications and transcription factors but not with components of the cohesin
complex in K562 cells. ENCODE ChIPseq data was retrieved (see Materials and methods) and box-plotted over five subgroups (A) of CTCF/CTCFL-
binding events. Shown are the FPKM values after subtraction of the corresponding input control values (see supplements) for active histone marks (B) and
known transcription factors (C). As a measure of open chromatin we compared the binding sites to DNase-seq experiments (D). Correlation with CTCF
interacting components of the cohesin complex was determined (E). Statistical evaluation is listed in Supplementary Table S3.
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Figure 2. CTCF and CTCFL show similar genome-wide distribution be-
tween two independent cell clones, but the binding sites show only a
weak overlap. (A) Annotation of the CTCFL binding sites to the asso-
ciated genomic feature for the ChIPseq results obtained from NIH3T3 &
P19 clones. (B) Four-way-Venn diagram showing the overlap of CTCF &
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compared to CTCF (Figure 2A). When comparing the cell
types in respect to CTCF, the association with TSSs is less
frequent in P19 cells with an increase for intergenic bind-
ing. Of all identified binding sites only 1,354 are bound by
both factors in both cell types, with varying levels of over-
lap between the datasets (Figure 2B). CTCF sites are gen-
erally more conserved between the cell lines with 41% of
3T3-CTCF sites also present in P19 (Figure 2C). In con-
trast, only 13% of the 3T3-CTCFL sites are shared (Fig-
ure 2C). Taken together, for each of the factors CTCF and
CTCFL we find a similar distribution in respect to the ge-
nomic features in the two cell types. Nevertheless, the bind-
ing site choice of CTCFL is highly cell-specific.
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Figure 3. Cell specificity of CTCFL deregulated genes. (A) Clustered
heatmap of genes that are deregulated by CTCFL in either NIH3T3 cells
or in P19 undifferentiated or in differentiated cells. Shown are normalized
log2-transformed changes of expression intensities (Supplementary Table
S4). Hierarchical clustering was performed using average linkage and co-
sine distance metric. (B) Three-way-Venn diagrams showing the overlap of
upregulated or downregulated genes between the three comparisons.
Cell-specific deregulation of target genes by conditional
CTCFL expression
Given the cell specific binding of CTCFL, we wanted to
know, whether this is reflected by a cell specific and CTCFL
induced change in expression profiles. Here we used the
above cell clones with conditional CTCFL expression. We
determined the expression profile in the absence and in the
presence of CTCFL induction. This we did for the NIH3T3
cell type as well as for the P19 embryonal carcinoma cells.
To further test our hypothesis that CTCFL binding is in
part determined by chromatin conformation, we differenti-
ated the P19 cell clone. P19 cells are stem cell-like in nature
and can easily be differentiated by retinoic acid treatment
(41). We used a long-term differentiation protocol (9 days)
to ensure changes in gene expression and chromatin compo-
sition, followed by CTCFL induction. Thus, we determined
the expression pattern for six conditions, NIH3T3, P19 un-
differentiated and P19 differentiated in the absence or after
induction of CTCFL in each case. Expression profiles were
compared and changes in expression for each of the genes
and each of the cell types were determined (Figure 3A, Sup-
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plementary Table S4). Log2-transformed fold changes were
calculated for the contrasts between CTCFL induced ver-
sus non-induced cells and sorted by hierarchical clustering
(Figure 3A). A striking pattern is evident, indicating that
genes induced or repressed by the expression of CTCFL are
highly cell and differentiation specific with almost no over-
lap between the cell types. Quantitative analysis of CTCFL
effected genes (Figure 3B) revealed similar magnitudes of
target genes being repressed or induced. Furthermore, cell
specificity is highly evident, with none of the repressed genes
or only three of the induced genes being shared by all of
the three cell types. Even within a single cell line, P19, be-
fore and after differentiation, the cell specificity of target
genes is highly obvious. In order to test for a functional rela-
tionship between CTCFL binding, open chromatin and dif-
ferential gene expression in CTCFL-expressing versus non-
expressing cells we compared the gene expression changes
of CTCFL-bound or CTCFL/H3K27ac co-bound genes
with the gene expression changes of the average gene (Sup-
plementary Figure S5). Especially CTCFL/H3K27ac co-
bound genes turned out to become significantly induced
(P-values of 2.00e–07 (NIH3T3); 3.36e–20 (p19 undiffer-
entiated); 1.54e–27 (p19 differentiated)) after expression of
CTCFL. These expression changes are not dramatic as
strong effects are only seen in a short and transient time
window (42).
Sequence preference of CTCFL binding
Besides cell specificity of CTCFL target genes, very few
genes regulated by CTCFL are shared between cell types
(Figure 3 and Supplementary Table S4). One gene to be
pointed out is the Adgrg1 gene (or GPR56), which was in-
duced in all three cases. This gene is known to play an im-
portant role in spermatogenesis. Mice deficient for GPR56
are impaired in male gonad development and in fertility
(43). Furthermore, GPR56 has been shown to be involved
in cancer progression (44). We reasoned that in this case,
CTCFL binding in three different cell types might be driven
by sequence specificity, in addition to chromatin features.
Previous identification of the binding consensus could not
detect differences between CTCF versus CTCFL (12). To
explore a possible sequence specificity for both factors we
followed a recently described workflow. In this study, EN-
CODE datasets were used in order to determine the top
1000 unique 14 bp core sequences bound in each case by
CTCF in at least 50 instances in the genome of K562 cells
(31). Subsequently, we mapped the CTCFL occupancy to
each of these sequences (Figure 4A). A general correlation
can be observed with the most frequently CTCF bound
sequences also showing the highest percentages of bound
CTCFL instances. In addition, single, highly CTCF bound
sequences without any CTCFL binding can be detected.
To identify possible small DNA sequence differences with
an impact on CTCFL occupancy, we grouped the individ-
ual core sequences with the highest CTCFL binding into
one class and a second class not bound by CTCFL, but
highly occupied by CTCF. For this we used DNA sequence
alignment and clustering algorithms (45). Comparison of
the top 20 sequences of both classes (Supplementary Fig-
ure S6) with Clustal Omega (data not shown) identified a
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Figure 4. DNA sequence contributes to differential CTCF and CTCFL
binding. ENCODE K562 binding data for CTCF and CTCFL were anal-
ysed utilizing the approach by Liu et al. (31). CTCF DNA binding se-
quences were grouped and sorted by their percentage of instances bound
by the CTCF factors in K562 cells. (A) Correlation plot showing the per-
centage of CTCF and CTCFL bound instances for each identified core
motif. (B) Identification of two highly similar sequences showing CTCF
occupancy in all instances but with differential CTCFL binding. Sequence
differences aremarked in red. The number of instances found in the human
genome are shown for the CTCF plus CTCFL binding sequence (left) and
the CTCFL only binding sequence (right).
single sequence from each of the two classes, respectively,
with higher similarity between each other than with any
other sequence of the two classes. These two highly sim-
ilar sequences, CCAGCAGAGGGCGC & TCAGTAGA
GGGCGC, show only a two base difference, but at the same
time strong differences in CTCFL occupancy (Figure 4 B,
crucial bases indicated in red; Supplementary Figure S6).
The presence of a T at positions 1 and 5 in the core se-
quence coincides with a complete lack of CTCFL occu-
pancy. However, when a C is located at these positions, 43%
of these sequences are bound by CTCFL in vivo. In contrast
to CTCFL, the level of CTCF occupancy is similarly high
for both sequences with 98% and 100% of these sequences
in the genome showing binding (Figure 4B). These results
lead us to propose that these two base changes may have an
influence on in vitro binding of CTCFL.
This hypothesis was tested by using double-stranded
oligonucleotides of a genomic region, 51 base pairs in
length, which centres on the identified CCAGCAGAGG
GCGC sequence. We chose the binding site HNR (named
for the neighbouring gene Hnrnpul1), which is strongly
bound by both, CTCF and CTCFL in vivo (Supplemen-
tary Figure S7A). We generated the specific mutation TC
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Figure 5. Specific point mutations determine CTCFL binding specificity. EMSA experiments were performed by incubating in vitro expressed CTCF or
CTCFL with 32P-labeled DNA probes. For competition experiments increasing amounts (2.5-, 10- and 40-fold) of un-labeled probes were used. Samples
were run on a 5% PAA gel and analysed by autoradiography. Arrows indicate the CTCF and CTCFL specific shifts. Two binding sites were chosen (HNR
and SLC). HNR is bound in vivo by both factors, whereas SLC is not bound by CTCFL. This difference is recapitulated by the in vitro binding. (A)
Replacing the ‘C’ at positions 1 and 5 by ‘T’ within the HNR site CCAGCAGAGGGCGC created HNRmB. As predicted, this site binds CTCF in vitro,
but is unable to bind CTCFL (top right). The reverse experiment replacing the ‘T’ at positions 1 and 5 by ‘C’ within the SLC site TCAGTAGAGGGCGC
created SLCpB. This generates a site bound by both factors (bottom left). (B) Pairwise comparison of wildtype and mutant sequence in competition
efficiency for CTCFL binding. Remaining shift signals in maximal competition (40-fold) are indicated (Signal). This supports the observation in (A), that
HNRmB lost its binding capacity to CTCFL, whereas SLCpB gained binding to CTCFL.
AGTAGAGGGCGC (HNRmB), which we predicted to be
impaired in CTCFL binding. Vice versa a 51-bp genomic
region centring on the non CTCFL-bound motif TCAG
TAGAGGGCGC, SLC (named for the gene Slc22a18as in
which it is located), was chosen. Endogenous chromatin
binding demonstrates CTCF occupancy, but no CTCFL
binding (Supplementary Figure S7B). We predicted that re-
placing the ‘T’ at positions 1 and 5 by ‘C’ (CCAGCAGA
GGGCGC -SLCpB) should allow for binding by CTCF
as well as by CTCFL. Electrophoretic mobility shift assays
(EMSA) were carried out with CTCF and CTCFL trans-
lated in vitro (Figure 5). As predicted, the oligonucleotides,
HNR and SLCpB, were bound by CTCF as well as by
CTCFL. Competition with an excess of unlabelled oligonu-
cleotide showed the specificity of binding. Use of the corre-
sponding variants, HNRmB and SLC, resulted in a similar
binding of CTCF, as determined from similar competition
efficiencies. In contrast, CTCFL did not bind to the two se-
quences containing the motif TCAGTAGAGGGCGC ir-
respective of its flanking sequence regions. To further chal-
lenge the conclusion that HNR is a binder for CTCF and
CTCFL and that CTCFL binding is specifically impaired in
the HNRmB mutation or that SLC does not bind CTCFL,
but achieves binding upon mutation to SLCpB, we set up
a pairwise competition assay for both wildtype and mutant
sequences in parallel. This allows for direct comparison of
the sequence pairs in binding affinity to CTCFL (Figure
5B). As expected, CTCFL binding to the HNR probe can
be efficiently competed by HNR (with only 8% of the sig-
nal remaining), whereas competition by the point mutant
HNRmB is less efficient. Similarly, CTCFL binding to the
SLCpB probe is efficiently competed by this probe (with
only 5% of the signal remaining), whereas competition by
the wildtype probe SLC is less efficient.
This supports our bioinformatics prediction, derived
from in vivo bound sequences, that specifically for CTCF
sites devoid of CTCFL binding, specificity is determined by
the very sequence and not somuch by chromatin conforma-
tion.
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Figure 6. CTCF/CTCFL specific zinc finger recognition. The 11 zinc fin-
gers are indicated by their coordinated zinc ion (Zn) and by four amino
acids at the alpha-helical positions −1, 2, 3 and 6 as counted from the
N-terminal to the C-terminal direction. These amino acids are in contact
with nucleotides of the binding sequence (49). The critical finger 6 is mag-
nified in the inset. Single black letters indicate identical amino acids for
CTCF and CTCFL. Double red letters indicate the amino acid found in
CTCF (first letter) and in CTCFL (second letter). The central fingers 4
to 7 are in contact with the consensus (bottom (47,48)). DNA upstream
oft the consensus is bound by fingers 8 to 11 and strongly bent (52). The
DNA sequence shown in black letters is bound by CTCF and by CTCFL,
whereas the sequence variant indicated by two red T nucleotides is bound
by CTCF, but never by CTCFL (see Figure 4).
DISCUSSION
CTCF is a highly conserved and essential factor involved in
regulating the crosstalk between distant chromatin regions.
A gene duplication event generated a related gene coding
for CTCFL (10). The DNA binding domain of both fac-
tors is very similar, harbouring eleven, almost identical zinc
fingers (9,13). CTCFL expression during spermatogenesis
and in some cancer types revealed a problem in understand-
ing mechanistically how this factor in the presence of the
ubiquitous factor CTCF is binding to chromatin. Binding
site specificity of CTCF in comparison to CTCFL has been
studied in several cases. By determining the consensus se-
quence of all sites bound by CTCF and of all sites bound
byCTCFL, almost identical consensus sequences have been
generated (12,46). In focussing on the number of consensus
sequences within CTCF or CTCFL bound regions, it has
been shown, that CTCFL preferentially binds to clustered
binding motifs (13). Co-binding by both factors explained
the apparent resistance of CTCF competition by CTCFL
binding. Clustered binding sites with CTCFL binding have
been found to be enriched at active promoters in cancer
cells (13). Thus, a specific sequence feature enriched in ac-
tive promoters could solely determine CTCFL binding se-
lectivity. Alternatively, or in addition, binding site selection
might be mediated by chromatin modification marks char-
acteristic for open and active chromatin. Here we find that
CTCFL binding sites are highly enriched for H3K27 acety-
lation, H3K4 di- and trimethylation, H3K79 dimethylation
and H3K9 acetylation plus the histone variant H2A.Z. In
case such modifications might contribute to binding site se-
lectivity one would expect, that different cell types with dif-
ferent repertoires of active genes, and therefore of active
chromatin regions, should respond to CTCFL expression in
a cell type specific manner. Here, we find that CTCFL tar-
get genes in mouse fibroblasts, embryonal carcinoma cells
and neuronal cells are almost not overlapping. This argues
for cell specific chromatin marks to contribute to CTCFL
function. Therefore we predicted that both, sequence fea-
tures as well as chromatin marks have a combined effect on
CTCFL selectivity.
One example for sequence driven selection is the GPR56
(Adgrg1) gene, which is activated by CTCFL in all three
cell types analysed. CTCFL facilitated induction of GPR56
might explain its activity in spermatogenesis (43) as well as
in cancer progression (44).
Our bioinformatics analysis identified nucleotide se-
quences always bound byCTCF, but never by CTCFL. This
is another argument for a sequence driven binding selectiv-
ity between CTCF and CTCFL. In order to test binding
specificity in vitro we chose CTCF and CTCFL bound se-
quences of the HNR and the SLC locus. Besides locus spe-
cific flanking sequences the nucleotide C to T change at con-
sensus positions 3 and 7 resulted in loss of CTCFL binding,
but not in CTCF binding. This clearly demonstrated a se-
quence driven selectivity in binding of the two CTCF fac-
tors.
Zinc finger mapping to the consensus sequence revealed
fingers 4 to 7 to be involved in recognition of the consensus
core sequence (47,48). Fingers 1 to 3 and 8 to 11 are pro-
posed to contact other regions, downstream and upstream
flanking the consensus (47). According to the structure of
zinc fingers, the amino acids of the alpha helical region are
numbered, with positions −1, 2, 3, and 6 being in contact
with nucleotides of the binding sequence (49). Within these
critical amino acids of fingers 4 to 7, only finger 6 shows an
amino acid difference between CTCFL and CTCF (9,46).
The critical amino acids are Q-1, G2, T3 andM6 for CTCF
and Q-1, G2, T3 and I6 for CTCFL (Figure 6, inset). Thus
position 6 of the alpha helix is methionine in case of CTCF
and isoleucine in CTCFL. The consensus nucleotides are
aligned with the contacting zinc fingers (Figure 6), indicat-
ing the potential vicinity between the nucleotides 3 and 7 of
the consensus and amino acid M6/I6 of the zinc finger 6.
This is in precise agreement with predictions based on em-
pirical calculations of pairwise amino acid–nucleotide in-
teraction energies, showing that the C/T at consensus posi-
tion 7 is contacted byCTCF zinc finger 6 (50). Furthermore,
the recent establishment of the structure of CTCF zinc fin-
gers bound toDNA (51), is in agreement with the alignment
shown in Figure 6. We propose that the single amino acid
difference between CTCF and CTCFL in zinc finger 6 con-
tributes to the binding specificity within the core consensus.
In summary, we conclude that the binding specificity of
the paralogous factors CTCF and CTCFL is determined by
three mechanisms. (a) DNA sequence driven specificity has
been described for double versus single binding sites (13)
in that CTCFL is preferentially bound at double sites. This
might be explained by a difference between both factors
in binding strength. CTCFL, potentially binding weakly,
might require the cooperative binding function of another
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CTCF molecule bound nearby. In contrast to this predic-
tion, in vitro we do not find a difference in binding affin-
ity. Both factors, when competed with an excess of binding
DNA, are competed with comparable DNA amounts (Fig-
ure 5). (b) Here, we find that subtle differences in the amino
acid sequence of the zinc fingers determine site-specific se-
lectivity. (c) The chromatin driven specificity of binding
demonstrated here as well, can be easily attributed to the
protein domains outside of the zinc finger region, as these
domains are quite different and therefore might differen-
tially interact with chromatin or with chromatin modifying
enzymes.
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